Back to peptides

BPC-157

aka Body Protection Compound 157, PL 14736, PL-10, PLD-116, Bepecin

Tissue RepairInjury RecoveryTendonLigamentMuscle GrowthGut HealthAnti-inflammatoryAngiogenesisTissue RepairWound Closure

Last reviewed April 27, 2026 by Doserr editorial team · 21 references on this page

Information on this page is sourced from published research and is for educational purposes only. It does not constitute medical advice.

TL;DR

  • What it is: A 15-amino-acid synthetic peptide derived from a protein found in human gastric juice.
  • What it's used for: Mostly used for injury recovery (tendons, muscle, gut). Evidence is rodent-only with three small uncontrolled human pilots.
  • Evidence level:limitedAnimal data only, no controlled human trials published.

Dose at a glance

BeginnerCommonHigher end
Per dose125-250 mcg250-500 mcg500-1000 mcg
Daily total125-250 mcg500 mcg750-1000 mcg
ScheduleOnce dailyOnce daily1-2x daily
Cycle length4 weeks4-8 weeks8-12 weeks

Synthesized from community-reported ranges. Not a recommendation. Route varies by compound — see Common route in What people report below.

Half-life
Less than 30 minutes (elimination t1/2 after IV and IM administration in rats and beagle dogs, PMID: 36588717). Limited human pharmacokinetic data.
Typical dose range
Doses below are from published research, not recommendations. Rodent studies: 10 pg/kg to 10 mcg/kg body weight once daily IP or IM. Oral rat studies: 0.16 mcg/mL in drinking water. Human pilot studies: 10-20 mg total dose (IV), 10 mg total dose (intravesical).
Route
Intraperitoneal (IP) most common in rodent research, intra-articular, intravesical, and IV in limited human pilot studies.
Evidence tier
limited

Animal or in-vitro studies only — no published human efficacy data.

What the research shows

Each topic links to the studies behind it. Click a topic to expand.

What we don't know yet

  1. No controlled human efficacy data exist, all efficacy findings are from animal models or small uncontrolled pilots (PMID: 40756949)
  2. Human pharmacokinetics are not characterized in peer-reviewed literature, half-life data are from rats and dogs (PMID: 36588717)
  3. Oral vs. injectable bioavailability in humans is unknown, animal data show approximately 14-19% IM bioavailability in rats and 45-51% in dogs
  4. Long-term human safety data are absent, the longest human follow-up is 6-12 months from a retrospective chart review (PMID: 34324435)
  5. Most published studies originate from a small number of research groups centered at the University of Zagreb, limiting independent replication

Run a calculation for this peptide

Reconstitution math, both directions.

Track this peptide

Log every dose, see your history, and save this protocol with one click.